DUBLIN, Ireland--(BUSINESS WIRE)--Amarin Corporation plc (NASDAQ:AMRN) today announced the opening of its research and development headquarters in Mystic, Connecticut in the United States. The new office will be responsible for Amarin’s research and development activities in cardiovascular disease which includes AMR101 for hypertriglyceridemia, planned to enter Phase 3 in 2009.